Solventum Corporation

SOLV Healthcare Medical Instruments & Supplies

Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.

Revenue
−7.01%
EPS
−101.0%
Free cash flow
+561.9%
Total debt
−90.1%

Quarter to September 2026, against a year earlier

91.42 4.24 +4.86%
Market cap
$14.8B
P/E
97.3×
Fwd P/E
47.7×
Dividend yield
—
F-score
5/9
Altman Z
2.22
Beneish M
−2.07
Dividend safety
n/a

Solventum Corporation (SOLV) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Solventum Corporation (SOLV) trades at a P/S ratio of 1.8×. Over the past ten years it has ranged from 1.0× (July 2024) to 1.9× (September 2026); the current reading is higher than 93% of that period. That is below the Medical Instruments & Supplies industry median of 2.5× and below the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 1.7× 19.54%
FY2024 1.4× (17.76%)
FY2023 1.7× 0.00%
FY2022 1.7× —

Quarterly newest first

Period P/S ratio Change
Sep 2026 1.8× 15.04%
Jun 2026 1.6× 16.45%
Mar 2026 1.4× (16.92%)
Dec 2025 1.7× 9.42%
11 more quarters

Against its own ten years

Low 1.0× High 1.9×
Ten-year median 1.5×
Current reading's percentile 93

P/S ratio against peers

Company P/S ratio
BAX Baxter International Inc. compare 1.1×
BLCO Bausch + Lomb Corporation compare 1.3×
AVTR Avantor, Inc. compare 1.5×
SOLV Solventum Corporation 1.8×
ATR AptarGroup, Inc. compare 2.3×
ALGN Align Technology, Inc. compare 2.7×
COO The Cooper Companies, Inc. compare 2.9×
WST West Pharmaceutical Services, Inc. compare 8.1×
RGEN Repligen Corporation compare 11.9×
Medical Instruments & Supplies industry median 2.5×
Healthcare sector median 3.5×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on SOLV